Introduction
============

Acute myeloid leukemia (AML) is a complex cancer characterized by uncontrolled proliferation and apoptosis of abnormal stem cells in the bone marrow (BM) and inhibition in the growth of normal hematopoietic cells [@B1],[@B2]. The diagnosis of AML mainly depends on the features of morphology, immunology, cytogenetics, and molecular biology (MICM). Despite the advancements in the treatment of leukemia, clinical outcome of AML remains unsatisfactory [@B3]. Cytogenetic alterations play crucial roles in the pathogenesis of AML and also act as vital biological markers in predicting prognosis for AML [@B4],[@B5]. However, there are approximately 40% *de novo* AML patients do not have clonal cytogenetic abnormalities, which was defined as cytogenetically normal AML (CN-AML) [@B6],[@B7]. Clinical outcome of CN-AML patients is quite heterogeneous from a few days to complete cure. Recently, several molecular biomarkers including *NPM1*, *CEBPA*, *C-KIT*, and *FLT3* mutations have provided helpful prognostic information for these patients [@B8]. Therefore, identifying novel genetic and epigenetic alterations which can recognize the patients who are at the risk of poor outcome is warranted to optimize treatment strategies [@B9],[@B10].

WNT/β-Catenin signaling pathway plays crucial roles in physiological processes including stem cell maintenance, cell differentiation, migration, apoptosis and proliferation during embryonic development [@B11],[@B12]. At the same time, abnormal regulation of Wnt/β-catenin signaling pathway also contributes to the development of human cancers including leukemia. Increasing studies have indicated that dysregulated Wnt pathway is associated with leukemogenesis and clinical outcome [@B13]-[@B16]. Overexpression of Wnt/β-catenin pathway genes or loss of Wnt antagonists promotes uncontrolled cell growth and survival [@B17]. Naked family (*NKD1* and *NKD2*) has been reported to function as a negative regulator of Wnt/β-catenin signaling pathway [@B18]. *NKD* binds and inactivates dishevelled, a scaffold protein that transduces the Wnt signal from the frizzled receptor to the destruction complex [@B19]. Decreased expression of *NKD2* caused by its promoter hypermethylation has been increasingly demonstrated in several solid tumors [@B19]-[@B22]. However, the pattern of *NKD2* expression and methylation in AML has not been explored yet. Therefore, we focused on the *NKD2* expression as well as methylation and their clinical significance in *de novo* patients with AML in the current study.

Materials and methods
=====================

Patients\' samples
------------------

A total of 113 patients with a diagnosis of *de novo* AML including 42 CN-AML were enrolled into the study approved by the Institutional Review Board of the Affiliated People\'s Hospital of Jiangsu University. The diagnosis and classification of the patients were based on the revised 2008 World Health Organization (WHO) criteria [@B23]. Clinical features of the patients were showed in Table [1](#T1){ref-type="table"}. Treatment protocol for AML patients was described previously [@B24]. A total of 9 AML patients achieved complete remission (CR) after induction therapy together with 24 healthy donors were also included. Follow-up data was obtained in 94 patients ranging from 1 to 58 months with a median of 7 months. Bone marrow (BM) were collected form all the patients and participants after written informed consents were obtained.

Cell line, cell culture and 5-aza-dC treatment
----------------------------------------------

Human leukemic cell line (THP1) was cultured in 1640 medium containing 10% fetal calf serum (ExCell Bio, Shanghai, China) and grown at 37°C in 5% CO~2~ humidified atmosphere. For epigenetic studies, 5-aza-2\'-deoxycytidine (5-aza-dC) (Sigma-Aldrich, Steinheim, USA) diluted in dimethyl sulfoxide (DMSO) was added in three flasks of THP1 cells (at a density of 5×10^5^ cells/ml in 10 ml) once a day at different final concentrations of 0 μM, 2 μM and 4 μM during 3 days. All cells were cultured until harvested for extraction of RNA and DNA.

RNA isolation, reverse transcription and RQ-PCR
-----------------------------------------------

BM mononuclear cells (BMMNCs) were extracted by Lymphocyte Separation Medium (TBD sciences, Tianjin, China). Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription (RT) was performed as reported previously [@B25],[@B26].

Real-time quantitative PCR (RQ-PCR) was performed on a 7500 Thermo cycler (Applied Biosystems, CA, USA). The reaction system with 20 μL volume consisted of H~2~O 6 μL, 10 μM of AceQ qPCR SYBR Green Master Mix (Vazyme Biotech Co., Piscataway, NJ, USA), 0.4 μM of ROX Reference Dye 2 (Invitrogen, Carlsbad, CA,USA),and 0.8 μM of primers (forward 5\'-ACAGGAGGTTGTCTGCACACG-3\' and reverse 5\'-GACTTGAGGAACTGCTTCTCCG-3\') [@B20]. The RQ-PCR reaction conditions were 95 °C for 5 min, followed by 40 cycles at 95 °C for 10 s, 65 °C for 30 s, 72 °C for 32 s, and 86 °C for 32 s to collect fluorescence, finally followed by 95 °C for 15 s, 60 °C for 60 s, 95 °C for 15 s, and 60 °C for 15 s. Both positive and negative controls were included in each assay. Relative *NKD2* expression levels were calculated using the following equation:
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DNA isolation, chemical modification and RQ-MSP
-----------------------------------------------

Genomic DNA was isolated using genomic DNA purification kit (Gentra, Minneapolis, MN, USA) and was modified using the CpGenome DNA Modification Kit (Chemicon, Ternecula, Canada) according to the manufacturer\'s instructions. The primers used for the methylated (M) \[(forward) 5\'-GATCGTAGGGGATAGTTTCGTGGC-3\'; (reverse) 5\'-AAAACAACTCTAACACCGCTCCCCG-3\'\] and unmethylaed (U) \[(forward) 5\'-TGGATTGTAGGGGATAGTTTTGTGGT-3\'; (reverse)5\'-CAAAAACAACTCTAACACCACTCCCCA-3\'\] [@B20]. Real-time quantitative methyaltion-specific PCR (RQ-MSP) reaction contained 0.8 μM of primers, 10 μM of AceQ qPCR SYBR Green Master Mix (Vazyme Biotech Co., Piscataway, NJ, USA), 0.4 μM of ROX Reference Dye 2 (Invitrogen, Carlsbad, CA, USA), and 20 ng of modified DNA was also performed a 7500 Thermo cycler (Applied Biosystems, CA, USA). The reaction condition was 95°C for 5 min, 40 cycles for 10 s at 95°C, 30 s at 62°C (M) or 64°C (U), 72°C for 30 s, and 80°C (M) or 76°C (U) for 30 s, eventually a melting program of one cycle at 95°C for 15 s, 60°C for 60 s, 95°C for 15 s, and 60°C for 15 s. The normalized ratio (N~M-NKD2~) was applied to assess the level of *NKD2* promoter methylation in samples. N~M-NKD2~ was calculated using the following formula:
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BSP
---

Bisulfite sequencing PCR (BSP) reaction system was composed of 1×PCR buffer (KCl 0.25 mM), dNTP Mixture 6.25 μM, primers 0.5 μM, hot start DNA polymerase 0.75 U (Takara, Tokyo, Japan), and modified DNA 20 ng. The primers for bisulfite modified NKD2 promoter were 5\'-TTTTGGAGTTAGTAGTGGGGG-3\' (forward) and 5\'-CACCAAAAACAACTCTAACACC-3\' (reverse). The program was carried out at 98°C for 10 s, 40 cycles for 10 s at 98°C, 30 s at 58°C, 72°C for 30 s, and followed by a final 7 min extension step at 72°C. The PCR products were analyzed on 2% agarose gels. Each purified product was cloned into pMD19-T Vector (Takara, Tokyo, Japan), and was transfected into DH5α competent cells (Vazyme Biotech Co., Piscataway, NJ, USA). Five clones from each sample were sequenced (BGI Tech Solutions Co., Shanghai, China).

HRMA and sequencing
-------------------

High-resolution melting analysis (HRMA) was performed on the LightScanner platform (Idaho Technology Inc., Salt Lake City, Utah, USA). *NRAS*or *KRAS*, *DNMT3A*, *IDH1/2*, *KIT*, and *NPM1* mutations were detected by HRMA [@B27]-[@B30]. All positive samples were confirmed by DNA direct sequencing. *FLT3-ITD* and *CEBPA* mutations were detected by direct DNA sequencing (BGI Tech Solutions Co., Shanghai, China) [@B31].

Statistical analyses
--------------------

Statistical analyses were performed using the SPSS 20.0 software package. Mann-Whitney\'s *U* test was carried to compare the difference of continuous variables between two groups. Pearson Chi-square analysis or Fisher exact test was employed to compare the difference of categorical variables. Correlation analysis between *NKD2* expression and prognosis was performed by Kaplan-Meier curves and Cox regression analysis. Receiver operating characteristic curve (ROC) and area under the ROC curve (AUC) were used to assess the value of *NKD2*expression in discriminating AML patients from controls. For all analyses, a two-tailed *P*\<0.05 was defined as statistically significant.

Results
=======

NKD2 expression in AML patients
-------------------------------

*NKD2* transcript level in AML patients (range 0.0000-57.9485, median 0.0000) was significantly lower as compared with controls (range 0.0000-3.6715, median 0.0082) which indicated that *NKD2* expression was down-regulated in AML (*P*=0.039, Fig. [1](#F1){ref-type="fig"}).

Discriminative capacity of NKD2 expression
------------------------------------------

ROC curve indicated that *NKD2* expression might serve as a biomarker for distinguishing whole-cohort AML patients from normal controls (AUC=0.628, 95% CI: 0.515-0.740, *P*=0.049, Fig. [2](#F2){ref-type="fig"}).

NKD2 methylation in AML patients
--------------------------------

*NKD2* methylation was detected in 101 AML patients and 24 controls with available DNA. *NKD2* methylation level in AML patients (median 0.0009, range 0.0000-25.2199) was significantly higher than controls (median 0.0005, range 0.0000-1.0000) (*P*=0.044, Fig. [3](#F3){ref-type="fig"}) which suggested that *NKD2* was hypermethylated in AML.

To further confirm RQ-MSP result, we selected 6 samples (2 with lowest methylation level, 2 with highest methylation level, and 2 selected randomly) to investigate the *NKD2* methylation density by BSP. Controls presented almost fully unmethylated *NKD2* promoter, while the two methylated AML patients presented higher density of *NKD2* methylation (Fig. [4](#F4){ref-type="fig"}). Moreover, *NKD2* methylation density in the tested samples was heavily correlated with *NKD2* methylation level (R=0.928, *P*=0.008).

NKD2 expression was regulated by its promoter methylation
---------------------------------------------------------

To determine the role of *NKD2* promoter methylation in regulating *NKD2* expression in AML, we analyzed the relationship between *NKD2* methylation and expression in AML patients. Significantly negative correlation was observed between *NKD2*expression and its promoter methylation in AML patients (R=-0.218, *P*=0.029, Fig. [5](#F5){ref-type="fig"}).

We further selected *NKD2*-methylated THP1 cell line treated by 5-aza-dC to further verify the epigenetic mechanism. Before 5-aza-dC treatment, THP1 showed weakly *NKD2* expression and highly methylated *NKD2* promoter. As expected, *NKD2* promoter methylation level was decreased, meanwhile, *NKD2* expression was significantly up-regulated after 5-aza-dC treatment (Fig. [6](#F6){ref-type="fig"}).

Clinical and laboratory characteristics of AML patients
-------------------------------------------------------

The whole cohort of AML patients were divided into two groups at the median level of *NKD2*expression: low *NKD2* expression (*NKD2*^low^) and high *NKD2* expression (*NKD2*^high^). The correlation between *NKD2* expression and clinical characteristics was presented in Table [1](#T1){ref-type="table"}. There were no significant differences in sex, age, platelets, white blood cells, hemoglobin and BM blasts between the *NKD2*^high^ and *NKD2*^low^ groups (*P*\>0.05). No significant differences were found between the two groups in the distribution of WHO subtypes, and karyotypic classifications. Moreover, no significant correlations were found between *NKD2* expression and nine gene mutations (*P*\>0.05).

Correlation between NKD2 expression and clinical outcome
--------------------------------------------------------

After induction therapy, there was no significant difference in complete remission (CR) rate between *NKD2*^low^ patients and *NKD2*^high^patients (*P*=0.419, Table [1](#T1){ref-type="table"}). Moreover, no significant differences were found between the two groups among both non-APL AML \[30% (11/26) vs. 37% (16/27), respectively, *P*=0.636\] and cytogenetically normal AML (CN-AML) patients \[27% (4/11) vs. 50% (14/14), respectively, *P*=0.199\]. The whole-cohort and non-APL AML showed no significant difference in both the overall survival (OS) (*P*=0.081 and 0.106) and leukemia-free survival (LFS) (*P*=0.516 and 0.376). However, among CN-AML patients, cases with low *NKD2* expression had significantly shorter OS (median 3 versus 11 months, respectively, *P*=0.029, Fig. [7](#F7){ref-type="fig"}) but not LFS (*P*=0.178) time than those with high *NKD2* expression. We further performed Cox regression analysis to determine the prognostic value of *NKD2* expression in CN-AML patients. Multivariate analysis including variables \[WBC (≥30×10^9^/L vs. \<30×10^9^/L), age (\>60 vs. ≤60 years old), gene mutations (mutant vs. wild-type), and *NKD2* expression (high vs. low)\] with *P*\<0.20 in univariate analysis, and disclosed that low *NKD2*expression and WBC were independent risk factor in OS but not LFS analyses among CN-AML patients (Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

Furthermore, the prognostic impact of *NKD2* expression was also confirmed by gene expression profiling (GEP) data (accession number GSE12417, <http://www.ncbi.nlm.nih.gov/geo/>) from two independent cohorts of adult CN-AML patients published by Metzeler et al using the online web tool Genomicscape (<http://genomicscape.com/microarray/survival.php>) [@B32]. Similarly, patients with low *NKD2* expression showed shorter OS as compared to those with high *NKD2* expression in both two cohorts (162 and 78 patients) (*P*=0.033 and 0.053, respectively, Fig. [8](#F8){ref-type="fig"}a and 8b).

Surveillance of NKD2 expression in follow-up AML patients
---------------------------------------------------------

To further investigated whether levels of *NKD2* factored in patients\' response to therapy, we followed *NKD2* expression of 9 patients with AML from the initial diagnosis to CR. Our study revealed that *NKD2* showed significantly increased level in post-CR than initial diagnosis in follow-up AML patients (*P*=0.024, Fig [9](#F9){ref-type="fig"}).

Discussion
==========

The activity of the Wnt pathway is controlled by extracellular and intracellular inhibitors mainly including secreted frizzled-related proteins (*SFRPs*), dickkopfs (*DKK*), SRY-box containing gene (*SOX*), and *NKD* family [@B19]. Frequent promoter hypermethylation of Wnt pathway inhibitor genes and their effect on gene expression have been revealed in malignant tumors [@B19]. Recently, accumulating evidence has revealed the direct role of *NKD2* in tumorigenesis. Reduced *NKD2* expression is found in osteosarcoma and has a significant role in driving tumor growth and metastasis [@B33]. *NKD2* suppresses breast cancer cell proliferation both in vitro and in vivo and induced G1/S arrest and inhibits Wnt signaling in breast cancer cells [@B20]. In human gastric cancer, *NKD2* restoration suppresses cell proliferation, colony formation, cell invasion and migration, induced G2/M phase arrest, and sensitizes cancer cells to docetaxel [@B34]. In addition, curcumin significantly upregulated the expression of *NKD2* in SW620 colorectal cancer cells and inhibited the proliferation of colorectal cancer cells, resulting in the down-regulation of crucial markers in the Wnt signaling [@B35]. Zhi Li et al suggested that *NKD2* is a direct target of miR-130b, and miR-130b regulated proliferation and apoptosis of osteosarcoma cells by targeting *NKD2* and regulating the Wnt signaling [@B36]. Moreover, long noncoding RNA *ZFAS1* repressed underlying targets *KLF2* and *NKD2* transcription to promote gastric cancer cells proliferation by interacting with *EZH2* and *LSD1/CoREST* [@B37]. Our previous studies have disclosed that *SOX17* and *SRFP1/2* expression was down-regulated in AML and low *SOX17* expression was associated with adverse prognosis in CN-AML patients [@B38]-[@B40]. Additionally, decreased *SFRP1* expression was found more frequently in the less well differentiated subgroups of AML and is associated with *NPM1* mutation in AML [@B39], whereas reduced *SFRP2* expression was correlated with intermediate/poor karyotypes in AML [@B40]. As far as we know, this is the first report about *NKD2* expression and its clinical significance in patients with AML.

In this study, we observed that down-regulation of *NKD2* expression was a frequent event in AML patients, which indicates that *NKD2* might act as tumor suppressor role as well in leukemogenesis. Obviously, function studies of *NKD2*in leukemia are needed to support our results. Although no significant associations were observed between *NKD2* expression and laboratory features as well as common gene mutations, survival analyses revealed that low *NKD2* expression were associated with shorter OS and LFS among CN-AML patients. Notably, dynamic monitoring the level of *NKD2* in 9 cases of patients illustrated that *NKD2* were significantly increased from the initial diagnosis to CR by mentioned therapeutic protocols. In recent years, clinical significance of *NKD2* expression has been increasingly investigated in various human cancers. Zhao et al demonstrated that decreased expression of *NKD2* was associated with a significantly worse OS in human osteosarcoma tumors [@B33]. These results together indicated that *NKD2* expression was a valuable predictor in assessing treatment outcome as well as status, and might serve as a criterion for the therapeutic evaluation in AML.

The regulation of *NKD2* expression is associated with the methylation of its promoter [@B21]. We found that *NKD2* methylation was a common event in AML patients and its role in silencing *NKD2* expression was confirmed in leukemic cell lines THP1. In addition, our study further observed that *NKD2* expression was negatively correlated with *NKD2* expression in clinical samples. Recently, the clinical significance of *NKD2* methylation has been also identified in several cancers [@B20],[@B21],[@B34]. In human breast cancer, *NKD2* methylation is associated with higher tumor stages [@B20]. Moreover, in gastric cancer, methylation of *NKD2* is significantly associated with the degree of cell differentiation, TNM stage, and distant metastasis and may serve as a poor prognostic predictor [@B34].

All in all, decreased *NKD2* expression inactivated by promotor hypermethylation is a common event in AML and is associated with adverse outcome in CN-AML patients.
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![*NKD2* expression and methylation in THP1 cell line before and after 5-aza-dC treatment. a: *NKD2* relative expression levels; b: *NKD2* relative methylation levels; c: *NKD2* methylation density before treatment; d: *NKD2* methylation density after 2 μM treatment; e: *NKD2* methylation density after 4 μM treatment.](jcav08p0460g006){#F6}
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![Prognostic value of *NKD2* expression using Gene expression profiling data (accession number GSE12417, <http://www.ncbi.nlm.nih.gov/geo/>) in CN-AML. a: data with 162 patients; b: data with 78 patients.](jcav08p0460g008){#F8}

![Changes of *NKD2* expression in follow-up AML patients (n=9) from the initial diagnosis to complete remission. White represents AML patients before therapy, black indicates complete remission after therapy.](jcav08p0460g009){#F9}

###### 

Comparison of clinical manifestations and laboratory features between AML patients with low and high *NKD2* expression.

  Patient\'s parameters                  High (n=56)        Low (n=57)         *P* value
  -------------------------------------- ------------------ ------------------ -----------
  Sex, male/female                       36/20              31/26              0.340
  Median age, years (range)              58 (15-86)         53 (10-93)         0.726
  Median WBC, ×10^9^/L (range)           22.7 (1.1-203.6)   6.75 (1.0-197.7)   0.066
  Median hemoglobin, g/L (range)         78.5 (40-133)      69.5 (34-142)      0.074
  Median platelets, ×10^9^/L (range)     48.5 (3-447)       40 (6-399)         0.916
  BM blasts, % (range)                   48.5 (5.5-94.5)    38 (3-92)          0.385
  CR (-/+)                               27/25              28/18              0.419
  WHO                                                                          0.865
  AML with t(8;21)                       4 (7%)             4 (7%)             
  APL with t(15;17)                      9 (16%)            13 (23%)           
  AML with inv(16)(p13q22)               0 (0%)             0 (0%)             
  AML with less differentiation          0 (0%)             1 (2%)             
  AML without maturation                 5 (9%)             3 (5%)             
  AML with maturation                    20 (36%)           17 (30%)           
  Acute myelomonocytic leukemia          12 (21%)           11 (19%)           
  Acute monoblastic/monocytic leukemia   4 (7%)             7 (12%)            
  Acute erythroid leukemia               2 (4%)             1 (2%)             
  Karyotype classification                                                     0.726
  Favorable                              12 (21%)           17 (30%)           
  Intermediate                           34 (61%)           30 (53%)           
  Poor                                   7 (13%)            8 (14%)            
  No data                                3 (5%)             2 (3%)             
  Karyotype                                                                    0.167
  normal                                 31 (56%)           20 (35%)           
  t(8;21)                                4 (7%)             4 (7%)             
  t(15;17)                               8 (14%)            12 (21%)           
  11q23                                  1 (2%)             0 (0%)             
  complex                                6 (11%)            9 (16%)            
  others                                 3 (5%)             10 (18%)           
  No data                                3 (5%)             2 (3%)             
  Gene mutation                                                                
  *CEBPA* (+/-)                          10/42              6/44               0.417
  *NPM1* (+/-)                           7/45               6/44               1.000
  *FLT3*-ITD (+/-)                       10/42              6/44               0.417
  *c-KIT* (+/-)                          2/50               1/49               1.000
  *NRAS*or*KRAS* (+/-)                   6/46               2/48               0.148
  *IDH1* or*IDH2* (+/-)                  3/49               4/46               0.713
  *DNMT3A* (+/-)                         6/46               3/47               0.264

WBC: white blood cells; AML: acute myeloid leukemia; CR: complete remission.

###### 

Univariate and multivariate analyses of prognostic factors for overall survival in CN-AML patients.

  prognostic factors         Univariate analysis   Multivariate analysis                          
  -------------------------- --------------------- ----------------------- ---------------------- -------
  age                        2.717 (1.504-4.912)   0.001                   1.897 (0.823-4.376)    0.133
  *NKD2*expression           0.444 (0.202-0.973)   0.043                   0.328 (0.127-0.849)    0.022
  WBC                        1.748 (0.991-3.083)   0.054                   2.489 (1.057-5.862)    0.037
  *FLT3*-ITD mutation        0.685 (0.272-1.727)   0.423                   \-                     \-
  *NPM1* mutation            0.933 (0.418-2.086)   0.867                   \-                     \-
  *CEBPA* mutation           1.346 (0.603-3.004)   0.468                   \-                     \-
  *c-KIT* mutation           0.391 (0.054-2.837)   0.353                   \-                     \-
  *NRAS*or*KRAS* mutation    1.096 (0.434-2.769)   0.847                   \-                     \-
  *IDH1* or*IDH2* mutation   1.672 (0.809-3.455)   0.165                   7.559 (1.897-30.129)   0.004
  *DNMT3A* mutation          0.762 (0.302-1.921)   0.564                   \-                     \-

###### 

Univariate and multivariate analyses of prognostic factors for leukemia-free survival in CN-AML patients.

  prognostic factors         Univariate analysis   Multivariate analysis                         
  -------------------------- --------------------- ----------------------- --------------------- -------
  age                        2.019 (1.111-3.671)   0.021                   2.086 (0.926-4.700)   0.076
  *NKD2*expression           0.565 (0.264-1.209)   0.141                   0.404 (0.168-0.973)   0.043
  WBC                        1.562 (0.879-2.778)   0.129                   2.280 (1.022-5.086)   0.044
  *FLT3*-ITD mutation        0.726 (0.288-1.829)   0.497                   \-                    \-
  *NPM1* mutation            0.820 (0.368-1.827)   0.628                   \-                    \-
  *CEBPA* mutation           1.035 (0.465-2.303)   0.933                   \-                    \-
  *c-KIT* mutation           0.386 (0.053-2.800)   0.346                   \-                    \-
  *NRAS*or*KRAS* mutation    0.994 (0.394-2.506)   0.990                   \-                    \-
  *IDH1* or*IDH2* mutation   1.265 (0.613-2.609)   0.525                   \-                    \-
  *DNMT3A* mutation          0.821 (0.326-2.069)   0.676                   \-                    \-
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